 Shares of Epizyme NASDAQ:EPZM were unchanged after the company reported Q2 results.Quarterly Results Earnings per share decreased 9.43 over the past year to 0.58, which beat the estimate of 0.61.Revenue of 2,467,000 decreased by 58.19 from the same period last year, which missed the estimate of 4,300,000.Outlook Earnings guidance hasnt been issued by the company for now.View more earnings on EPZMRevenue guidance hasnt been issued by the company for now.Price Action Companys 52-week high was at 27.82Companys 52-week low was at 9.73Price action over last quarter: down 21.35Company Description Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma NHL, Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias PRMT5 inhibitor.See more from Benzinga Recap: Cinemark Q2 Earnings Recap: Mallinckrodt Q2 Earnings Earnings Scheduled For August 4, 2020C 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 